LoginRegister

    Indivior signs deal to sell schizophrenia drug Perseris in Canada

    GarimaWritten by Garima   |  
    Indivior signs deal to sell schizophrenia drug Perseris in Canada




    Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults.

    U.S: British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

    Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults.


    The drug delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended.





    Indivior has been looking to reduce its dependence on its best-selling Suboxone film after the opioid addiction treatment was hit by steep market share losses to generic rivals.

    Indivior, which gets most of its revenue from Suboxone in the United States, was indicted last month for illegal marketing of Suboxone in the U.S. and was fined $3 billion.

    Read Also: Indivior to launch Sublocade; maintains revenue forecast



    British drugmaker IndiviorCanadaFDAGeorge VargheseHLS TherapeuticsIndiviorlicensing agreementopioidopioid use disorderPerserisPerseris canadarisperidoneschizophreniaschizophrenia drugSuboxoneSubstance dependencetreatmentUnited StatesUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X